List of Marijuana/Cannabinoid-Derived Drugs Companies in Australia - 3

Botanix is an ASX-listed dermatology company based in Philadelphia and Phoenix (USA) that is committed to the development and commercialisation of novel treatments for common skin diseases and infections. The Company’s lead product is a novel treatment for primary axillary hyperhidrosis, a medical condition where excessive sweating occurs beyond what is needed to maintain body temperature, which impacts the lives of more than 15 million people in the US alone. This product is backed by successful Phase 3 clinical studies, is already approved in Japan, and is in the final stages of US regulatory clearance. The broader clinical pipeline targets unmet needs in dermatology (including acne, rosacea and dermatitis) as well as infections, and are underpinned by well-controlled, randomised clinical trials. Botanix has attracted a world-class team and significant capital to support the development and commercialisation of its products.

Founded in 1975, IDT Australia is a publicly listed Australian pharmaceutical manufacturing company, based in Boronia Victoria. Our experienced and awarded team of scientists and specialists provide a flexible and comprehensive service, focussed in our three strategic pillars: Active Pharmaceutical Ingredient synthesis design, scale up and cGMP manufacture including high potent molecules Specialty Orals novel and early stage design, formulation and cGMP manufacturing specifically targeting neuro disorders Advanced Technology, complex formulations for novel injectable drug development through to cGMP manufacture. This pillar includes RNA and Antibody Drug Conjugates. IDT Australia also has a fully equipped laboratory approved to TGA and FDA standards to develop, validate and operate GLP analytics for release, process validation and stability. IDT Australia has labelling and packaging capacity and capability and specialises in clinical trial labelling and packing.

Incannex is a clinical-stage pharmaceutical development company focused on discovering and developing life-changing medicines for patients struggling with serious, chronic diseases and limited treatment options. A leader in innovating proprietary cannabinoid pharmaceuticals and psychedelic-based therapies, we are developing medicines with the potential to alter the lives of patients suffering from obstructive sleep apnea (OSA), generalized anxiety disorder (GAD), and inflammatory disorders such as rheumatoid arthritis (RA). Working together in these relatively new fields with clinical, scientific, and drug development experts, we are efficiently innovating big solutions that are specifically designed and formulated to make a meaningful difference in patients' lives. Founded in 2015 and headquartered in Melbourne, Australia, we are expanding in the U.S. and worldwide to help more patients and their families. Incannex trades on the Nasdaq Global Market under the symbol IXHL.